AHL
LCTX icon

Abel Hall LLC’s Lineage Cell Therapeutics LCTX Stock Holding History

Abel Hall LLC’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.5K Buy
+13,090
New +$14.5K ﹤0.01% 885

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
HA
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
Connecticut Wealth Management
Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return
BWCS
Beirne Wealth Consulting Services Shelton, Connecticut $505M AUM 16.24% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return

Abel Hall LLC's LCTX Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 13,090 shares worth $12.5K. The stake represents ﹤0.01% of the portfolio and ranks #885 among its holdings.

15 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Abel Hall LLC held 13,090 shares of Lineage Cell Therapeutics worth $12.5K as of Q3 2026.
  • Lineage Cell Therapeutics was a new Abel Hall LLC position in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Abel Hall LLC's portfolio in Q3 2026, its #885 holding.
  • 15 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.